Zoetis reported strong revenue growth and raised its guidance, though net income showed weakness.Key PointsAdjusted earnings per share topped analyst estimates.Net income fell 7% year over year to $624 million.Full-year guidance for revenue and adjusted net income was raised.Animal health specialist Zoetis (ZTS 6.70%) posted second-quarter earnings on Tuesday that topped analysts' consensus estimates on both top and bottom lines. While revenue was up 8% year over year net income fell by 7% to $624 million d ...

Zoetis (ZTS) came out with quarterly earnings of $1.56 per share, beating the Zacks Consensus Estimate of $1.49 per share. This compares to earnings of $1.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.70%. A quarter ago, it was expected that this animal health company would post earnings of $1.34 per share when it actually produced earnings of $1.38, delivering a surprise of 2.99%.Over the last four quarters, the compan ...

2 nd Quarter 2024 Financial Results August 6, 2024 Forward-Looking Statements This presentation contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, future operating or financial performance; future guidance, future operating models, R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development and expected timing of product launches; disruptions in our global supply chain; ...

EXHIBIT 99.1 Zoetis Announces Second Quarter 2024 Results • Reports Revenue of $2.4 Billion, Growing 8%, and Net Income of $624 Million, or $1.37 per Diluted Share, Decreasing 7% and 6%, Respectively, on a Reported Basis for Second Quarter 2024 • Delivers 11% Operational Growth in Revenue and 18% Operational Growth in Adjusted Net Income for Second Quarter 2024 • Reports Adjusted Net Income of $711 Million, or Adjusted Diluted EPS of $1.56, for Second Quarter 2024 • Raises Full Year 2024 Revenue Guidance to ...

Zoetis (ZTS) ended the recent trading session at $182.42, demonstrating a +1.32% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily loss of 1.37%. Elsewhere, the Dow lost 1.21%, while the tech-heavy Nasdaq lost 2.3%.Prior to today's trading, shares of the animal health company had gained 2.53% over the past month. This has outpaced the Medical sector's gain of 0.74% and the S&P 500's gain of 1.11% in that time.The investment community will be closely monitorin ...

Wall Street analysts forecast that Zoetis (ZTS) will report quarterly earnings of $1.49 per share in its upcoming release, pointing to a year-over-year increase of 5.7%. It is anticipated that revenues will amount to $2.3 billion, exhibiting an increase of 5.6% compared to the year-ago quarter.Over the last 30 days, there has been an upward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their i ...

The market expects Zoetis (ZTS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Augu ...

The most recent trading session ended with Zoetis (ZTS) standing at $179.84, reflecting a -0.51% shift from the previouse trading day's closing. The stock's performance was behind the S&P 500's daily gain of 1.11%. Elsewhere, the Dow gained 1.64%, while the tech-heavy Nasdaq added 1.03%.Coming into today, shares of the animal health company had gained 2.44% in the past month. In that same time, the Medical sector lost 0.54%, while the S&P 500 lost 1.16%.The investment community will be closely monitoring th ...

Dublin, July 11, 2024 (GLOBE NEWSWIRE) -- The "Veterinary Pharmaceutical Manufacturing in Australia - Industry Market Research Report" report has been added to ResearchAndMarkets.com's offering.This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry key players and their market shares. Veterinary pharmaceutical manufacturers have endured their ...

Vesnaandjic/E+ via Getty Images Zoetis (NYSE:ZTS) is a leading animal pharmaceutical company, primarily focused on both companion pets and livestock. Zoetis boasts a robust portfolio of long-lasting blockbusters, benefiting from lower R&D costs and quicker development timelines compared to human pharmaceuticals. However, valuation concerns persist amidst reliance on key drug launches for future growth. One-Minute Summary of Zoetis' Business Here are some key highlights of Zoetis' business and industry i ...